Search Results - "Wigg, A"

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis by Wigg, A J, Roberts-Thomson, I C, Dymock, R B, McCarthy, P J, Grose, R H, Cummins, A G

“…BACKGROUND Small intestinal bacterial overgrowth may contribute to the development of non-alcoholic steatohepatitis, perhaps by increasing intestinal…”
Get full text

Real‐world outcomes of unrestricted direct‐acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience by Haridy, J., Wigg, A., Muller, K., Ramachandran, J., Tilley, E., Waddell, V., Gordon, D., Shaw, D., Huynh, D., Stewart, J., Nelson, R., Warner, M., Boyd, M., Chinnaratha, M. A., Harding, D., Ralton, L., Colman, A., Liew, D., Iyngkaran, G., Tse, E.

“…Summary In March 2016, the Australian government offered unrestricted access to direct‐acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) to…”
Get full text

Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes by Liu, H.Y.-h., Lee, Y.-y.D., Sridharan, S., Wang, W., Khor, R., Chu, J., Oar, A., Choong, E.S., Le, H., Shanker, M., Wigg, A., Stuart, K., Pryor, D.

“…Standard curative options for early-stage, solitary hepatocellular carcinoma (HCC) are often unsuitable due to liver dysfunction, comorbidities and/or tumour…”
Get full text

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15) by McCaughan, G. W., Thwaites, P. A., Roberts, S. K., Strasser, S. I., Mitchell, J., Morales, B., Mason, S., Gow, P., Wigg, A., Tallis, C., Jeffrey, G., George, J., Thompson, A. J., Parker, F. C., Angus, P. W.

“…Summary Background Antiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. Aims To examine the…”
Get full text

Poor adherence to hepatitis B screening protocols prior to rituximab; a multicentre South Australian study by Hall, S.A.L, Shaikh, A, Karapetis, C, Coghlan, D, Chinnaratha, A, Tantiongco, M, Teh, K, Woodman, R, Wigg, A

Get full text

Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis by Chinnaratha, M. A., Chaudhary, S., Doogue, M., McCormick, R. J., Woodman, R. J., Wigg, A. J.

“…Background Hepatic osteodystrophy (HO) is a major complication of cirrhosis. However, the prevalence of HO in a general cirrhotic patient population is not…”
Get full text

165 THE EFFECT OF OBESITY, RENAL DYSFUNCTION AND ADVANCED AGE ON LONG-TERM SURVIVAL IN PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION by De Sciscio, P, De Sciscio, M, Lau, S.Y, Wigg, A

Get full text

Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study by Kennedy, N. A., Rodgers, A., Altus, R., McCormick, R., Wundke, R., Wigg, A. J.

“…Background Surveillance for hepatocellular carcinoma (HCC) with 6‐monthly ultrasound is a standard of care for higher‐risk patients with viral hepatitis…”
Get full text

Rising incidence of hepatitis B-related hepatocellular carcinoma in South Australia: 1996-2010 by Chinnaratha, M. A., Graham, C., Fraser, R. J. L., Woodman, R. J., Wigg, A. J.

“…Background Chronic hepatitis B virus (HBV) infection is likely to be an important driver of increasing hepatocellular carcinoma (HCC) incidence in Australia…”
Get full text

Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/− ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis –Final results of the REV1TAL study by Lubel, J.S, Pianko, S, Thompson, A, Strasser, S, Dore, G, Stuart, K, MacQuillan, G, Iser, D, Mitchell, J, Gazzola, A, Chivers, S, Mishra, G, Gow, P, George, J, Gough, J, Tse, E, Zekry, A, Levy, M, Fragomeli, V, Morales, B, Sasadeusz, J, Nazareth, S, Bollipo, S, Jones, T, Wade, A, Cheng, W, Wigg, A, Roberts, S

Get full text

Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: A multicenter, exploratory analysis by Silva, M.F, Sapisochin, G, Strasser, S.I, Hewa-Geeganage, S, Chen, J, Wigg, A.J, Jones, R, Saraiva, R, Kikuchi, L, Carrilho, F, Fontes, P.R.O, Charco, R

“…Abstract Background and aim The current guideline of the American Association for the Study of Liver Diseases recommends liver resection for…”
Get full text

Chronic Kidney Disease Following Liver Transplantation: A South Australian Experience by Ramachandran, J, Juneja, R, John, L, Dutta, A.K, Chen, J.W, Woodman, R.J, Wigg, A.J

“…Abstract The incidence of chronic kidney disease (CKD) and its impact on survival have not been widely studied in the Australian liver transplant (OLT)…”
Get full text

Gastrointestinal: Embedded metal biliary stent by Mangira, D, Wigg, AJ

Get full text

Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of Cathepsin B through Structure-Based Drug Design by Greenspan, Paul D, Clark, Kirk L, Tommasi, Ruben A, Cowen, Scott D, McQuire, Leslie W, Farley, David L, van Duzer, John H, Goldberg, Ronald L, Zhou, Huanghai, Du, Zhengming, Fitt, John J, Coppa, David E, Fang, Zheng, Macchia, William, Zhu, Lijuan, Capparelli, Michael P, Goldstein, Robert, Wigg, Andrew M, Doughty, John R, Bohacek, Regine S, Knap, Ania K

“…Cathepsin B is a member of the papain superfamily of cysteine proteases and has been implicated in the pathology of numerous diseases, including arthritis and…”
Get full text

Heterozygous recipient and donor HFE mutations associated with a hereditary haemochromatosis phenotype after liver transplantation by Wigg, A J, Harley, H, Casey, G

“…We observed the development of phenotypic hereditary haemochromatosis in a non-hereditary haemochromatosis liver transplant recipient, following…”
Get full text

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward by Muller, K., Rodgers, A., Wundke, R., Waddell, V., Altus, R., Gordon, D. L., Wigg, A.

“…Background:  Hepatitis C treatment is successful in 40–80% of patients in drug sponsored registration trials. However, few studies have examined treatment…”
Get full text

642 BARCELONA-CLINIC-LIVER-CANCER (BCLC) STAGING AND ACTUAL THERAPY RECEIVED IN HIV-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), COMPARING DIAGNOSIS PRE-2006 AND 2006 AND LATER by Merchante, N, Kikuchi, L, Marks, K, Rivero, A, Palys, E, Mata, R, Wigg, A, Vachon, M.-L, Silva, M, Márquez-Molero, M, Jain, M, Goetz, M, Sherman, M, Bräu, N

Get full text

Faecal immunological test blues: is there a psychiatric morbidity associated with the National Bowel Cancer Screening Program? by Wigg, L., Chaudary, J., Wigg, A. J.

Get full text

Changing incidence of primary total hip arthroplasty and total knee arthroplasty for primary osteoarthritis by Wells, V.M., Hearn, T.C., McCaul, K.A., Anderton, S.M., Wigg, A.E.R., Graves, S.E.

“…This study reports on the incidence of primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) for primary osteoarthritis in Australia…”
Get full text

Is coeliac disease a confounding factor in the diagnosis of NASH? by GRIECO, A, MIELE, L, PIGNATARO, G, POMPILI, M, RAPACCINI, G L, GASBARRINI, G

“…[...]they made no attempt to exclude the possibility of coeliac disease (CD) which can also be associated with altered intestinal permeability even when the…”
Get full text